🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#TumorBoardTuesday In this holiday season, I am so ready to spend an hour smiling😀laughing😆and learning🧑🏼‍🎓for our next session 📢Join us Tuesday, 12-10-24 at 8PM ET as Balazs Halmos & Angelica D'Aiello, MD🗣️periOp mgmt of resectable #NSCLC RT and bring others into the discussion‼️

My Top Lung Cancer Trials of 2024 #LCSM OncoAlert The Cancer News Happy New Year !!! 1. LAURA: In this phase-3 trial, pts with unresectable EGFR-mutated stage III NSCLC were randomized to osimertinib or placebo post chemo-RT ➡️↑ PFS with Osimertinib bit.ly/4iZGUXt

Only 12 MORE DAYS to submit your application for the ABCTS/STS Pipeline Scholarship Program! This is an incredible opportunity! But don’t take our word for it, hear from 2024 scholarship recipient @JustinOlivera_1 about his experience at The Brigham and Women’s Hospital!

Pretty important and consistent information on the importance of increasing focus on treating lung cancer Drew Moghanaki Elliot Servais, MD, FACS Brendon Stiles Shanda Blackmon, MD, MPH CTSurgSocMedNetwork The Society of Thoracic Surgeons

BP Fistula Median Stern 2025 youtu.be/LSruSGXkPbg?si… via YouTube Management of a Bronchopleural Fistula after a prior Pneumonectomy where the patient was left with a long mainstay bronchial stump; a practical approach...

Calling all future Cardiothoracic surgeons! Virtual interview dates for the Thoracic-track fellowship @montefioreNYC @montefioreCTS will take place on March 14 and 21. We look forward to meeting you and sharing more about our clinically robust, outstanding training program!

Our program Lahey Hospital has long advocated for “CT lung screening” over “lung cancer screening”. Highlighting potential for important findings besides cancer Our group showed ~25% of those scanned based on NCCN criteria have marked emphysema and/or coronary calcifications.

"Denial of Access to CT Screening for Nonsmokers Is Unjust". jto.org/article/S1556-…

Saturday mornings are for discussions about early stage non-small cell lung cancer by Brendon Stiles #TTLC25

Nice to see Jorge Humberto Rodríguez Quintero MD, MPH paper trending in JTO & JTO CRR JTOCRR! Not perfect data set, but important point to not exclude cT3/4N2 patients from neoadj/surgery based upon IIIB designation alone! jtocrr.org/article/S2666-… Albert Einstein College of Medicine - Official Montefiore Health System

Some final thoughts after an incredible week where we were able to perform 9 life-saving operations (3 of which were done minimally invasive) ranging from simple valve repair/replacement to triple valve, aortic root, and aortic arch interventions.

Anterior gastropexy during minimally invasive paraesophageal hernia repair is superior to no gastropexy in regard to 1-year recurrence. ja.ma/4iLqRLU

Real world analysis of osimertinib vs afatinib in atypical #EGFR NSCLC Lung Cancer Journal. Outcomes varied by specific mutation: for G719X, afatinib had better outcomes (time to discontinuation 20.3m vs 9.4m) but for L861Q, osimertinib had an advantage. lungcancerjournal.info/article/S0169-…

This morning Dr. Goldstein received the The ISHLT 2025 Francis D. Pagani Endowed Mentorship Award for his tireless effort and commitment to mentoring the next generation of heart failure surgeons. 👏 #ISHLT2025

Retrospective study of neoadjuvant immunotherapy for 112 pts with stage III borderline resectable NSCLC JAMA Oncology. Included stage III with T4 and/or N2/3 NSCLC and 75% underwent surgery with 29% pCR, 42.2% MPR, mEFS 52.6m. Impressive to note that all N3 achieved ypN0.

Lots to think about! -If OS in CM816 shows similar improvement to KN671, should it be preferred regimen? -Will data dispel perceived need for adjuvant ICI after pCR? -Will neoadj TKIs move the needle? -Shouldn't we double down on increasing systemic therapy induced pCR? #ASCO25

Congrats on terrific presentation for Dr. Chaft Jamie Chaft on the 3-arm NEOADAURA trial showing much improved MPR/nodal downstaging by neoadj osi and chemo/osi vs chemo alone (which is pitiful on its own btw..) and excellent EFS for pts achieving MPR We will be scratching our

~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/

Perhaps a new upcoming quality metric? Surgeries > 8 weeks from suspicious CT SCAN for early stage NSCLC had worse survival!!!! AATS AATS ED The Society of Thoracic Surgeons American College of Surgeons Kaiser Permanente Research NorCal Kaiser Permanente Bernard J. Tyson School of Med UCSF Surgery

In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN phase 3 trial results and Research